GlaucomaVision and hearingDrug
What this study is
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
What's being tested
- Xiidra (Lifitegrast ophthalmic solution) 5%
Intervention · DRUG
FDA approved lifitegrast opthalmic solution eye drop
Study details
- Sponsor
- University of California, Los Angeles
- Conditions
- Glaucoma · Ocular Surface Disease
- Enrolling
- 75 people
- Starts
- 2021-04-01
- Est. completion
- 2026-12-01
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers AcceptedYou may qualify if
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
You can't join if
- History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
- Current use of topical cyclosporine
- Current use of topical steroids
- Incisional ocular surgery within 6 months
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openDoheny Eye Center UCLA
Fountain Valley, California, United States
- Benjamin B Bert, MD · Contact7149631444JanettMendez@mednet.ucla.edu
Recruiting
Study team
Sponsor
University of California, Los Angeles
Study ID 19-000843
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.